Specific transduction of hiv-susceptible cells for CCR5 knockdown and resistance to HIV infection: A novel method for targeted gene therapy and intracellular immunization

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 2, 2009, Pages 152-161

  Anderson, Joseph S ^a,b   Walker, Jon ^a   Nolta, Jan A ^a   Bauer, Gerhard ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Oak Park Research Building ^*  (United States)

Author keywords

CCR5 shRNA; HIV gene therapy; HIV preexposure prophylaxis; Lentiviral vector; Targeting vector

Indexed keywords

CHEMOKINE RECEPTOR CCR5; SINDBIS VIRUS NONSTRUCTURAL PROTEIN 4;

ARTICLE; CELLULAR IMMUNITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; VIRAL GENE THERAPY;

ANIMALS; ANTI-HIV AGENTS; CELL LINE; GENE KNOCKDOWN TECHNIQUES; GENE THERAPY; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; LENTIVIRUS; MICE; MICE, KNOCKOUT; MICE, SCID; RECEPTORS, CCR5; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC;

EID: 70349683000     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b010a0     Document Type: Article

References (51)

1. Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother. 2000;44:2475-2484.
2. Martinez-Picado J, DePasquale MP, Kartsonis N, et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci U S A. 2000;97:10948-10953.
3. Winters MA, Baxter JD, Mayers DL, et al. Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS. Antivir Ther. 2000;5:57-63.
4. Lafeuillade A, Poggi C, Hittinger G, et al. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates. HIV Med. 2002;2:231-235.
5. Marks K, Gulick RM. New antiretroviral agents for the treatment of HIV infection. Curr HIV/AIDS Rep. 2004;1:82-88.
6. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature. 2008;455:613-619.
7. Lee MT, Coburn GA, McClure MO, et al. Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol. 2003;77:11964-11972.
8. Bai J, Gorantla S, Banda N, et al. Characterization of anti- CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Mol Ther. 2002;1: 244-254.
9. Ding SF, Lombardi R, Nazari R, et al. A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and transdominant negative mutant Gag and Env proteins. Front Biosci. 2002;7:a15-a28.
10. Lee NS, Dohjima T, Bauer G, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol. 2002;20:500-505.
11. Martinez MA, Gutierrez A, Armand-Ugon M, et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS. 2002;16:2385-2390.
12. Michienzi A, Li S, Zaia JA, et al. A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci U S A. 2002;99: 14047-14052.
13. Novina CD, Murray MF, Dykxhoorn DM, et al. siRNA-directed inhibition of HIV-1 infection. Nat Med. 2002;8:681-686.
14. Cordelier P, Morse B, Strayer DS. Targeting CCR5 with siRNAs: using recombinant SV40-derived vectors to protect macrophages and microglia from R5-tropic HIV. Oligonucleotides. 2003;13:281-294.
15. An DS, Donahue RE, Kamata M, et al. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci U S A. 2007;104:13110-13115.
16. Anderson J, Akkina R. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection. Gene Ther. 2007;14:1287-1297.
17. Kumar P, Ba HS, Kim SS, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell. 2008;134: 577-586.
18. ter Brake O, Legrand N, von Eije KJ, et al. Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-) gammac(-/-)) mouse model. Gene Ther. 2009;16:148-153.
19. Kohn DB, Bauer G, Rice CR, et al. A clinical trial of retroviral-mediated transfer of a Rev-responsive element decoy gene into CD34+ cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood. 1999;94:368-371.
20. Bauer G, Selander D, Engel B, et al. Gene therapy for pediatric AIDS. Ann NY Acad Sci. 2000;918:318-329.
21. Humeau L, Binder GK, Lu X, et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther. 2004;9:902-913.
22. Anderson J, Li MJ, Palmer B, et al. Safety and efficacy of a lentiviral vector containing three anti-HIV genes-CCR5 ribozyme, tat-rev siRNA, and TAR decoy-in SCID-hu mouse-derived T cells. Mol Ther. 2007;15: 1182-1188.
23. Mitsuyasu RT, Merigan TC, Carr A, et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med. 2009;5: 285-292.
24. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806-811. (Pubitemid 28099681)
25. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494-498.
26. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996;2: 1240-1243.
27. Liu R, Paxton W, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell. 1996;86:267-377.
28. Naif HM, Cunningham AL, Alali M, et al. A human immunodeficiency virus type 1 isolate from an infected person homozygous for CCR5D32 exhibits dual tropism by infecting macrophages and MT2 cells via CXCR4. J Virol. 2002;76:3114-3124.
29. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N Engl J Med. 2009;360: 692-698.
30. Hatziioannou T, Delahaye E, Martin F, et al. Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hum Gene Ther. 1999;10:1533-1544.
31. Jiang A, Dornburg R. In vivo cell type-specific gene delivery with retroviral vectors that display single chain antibodies. Gene Ther. 1999;6: 1982-1987.
32. Engelstadter M, Bucholz CJ, Bobkova M, et al. Targeted gene transfer to lymphocytes using murine leukaemia virus vectors pseudotyped with spleen necrosis virus envelope proteins. Gene Ther. 2001;8: 1202-1206.
33. Lavillette D, Russell SJ, Cosset F-L. Retargeting gene delivery using surface-engineered retroviral vector particles. Curr Opin Biotechnol. 2001;12:461-466.
34. Lin AH, Kasahara N,WuW, et al. Receptor-specific targeting mediated by the coexpression of a targeted murine leukemia virus envelope protein and a binding-defective influenza hemagglutinin protein. Hum Gene Ther. 2001;12:323-332.
35. Zhong Q, Oliver P, Huang W, et al. Efficient c-kit receptor-targeted gene transfer to primary human CD34-selected hematopoietic stem cells. J Virol. 2001;75:10393-10400.
36. Maurice M, Verhoeyen E, Salmon P, et al. Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood. 2002;99: 2342-2350.
37. Chandrashekran A, Gordon MY, Casimir C. Targeted retroviral transduction of c-kit+ hematopoietic cells using novel ligand display technology. Blood. 2004;104:2697-2703.
38. Verhoeyen E, Wiznerowicz M, Olivier D, et al. Novel lentiviral vectors displaying early-acting cytokines selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells. Blood. 2005;106:3386-3395.
39. Yang L, Bailey L, Baltimore D, et al. Targeting lentiviral vectors to specific cell types in vivo. Proc Natl Acad Sci U S A. 2006;103:11479-11484.
40. Yang L, Yang H, Rideout K, et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol. 2008;26: 326-334.
41. Silva FAD, Costa MJL, Corte-Real S, et al. Celltype-specific targeting with Sindbis pseudotyped lentiviral vectors displaying anti-CCR5 singlechain antibodies. Hum Gene Ther. 2005;16:223-234.
42. Ohno K, Sawai K, Iijima Y, et al. Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat Biotechnol. 1997;15:763-767.
43. Morizono K, Bristol G, Xie YM, et al. Antibody-directed targeting of retroviral vectors via cell surface antigens. J Virol. 2001;75: 8016-8020.
44. Iijima Y, Ohno K, Ikeda H, et al. Cell-specific targeting of a thymidine kinase/gancyclovir gene therapy system using a recombinant Sindbis virus vector. Int J Cancer. 1999;80:110-118.
45. Morizono K, Xie Y, Ringpis GE, et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med. 2005;11:346-352.
46. Morizono K, Chen IS. Targeted gene delivery by intravenous injection of retroviral vectors. Cell Cycle. 2005;4:854-856.
47. Liang M, Pariente N, Morizono K, et al. Targeted transduction of CD34+ hematopoietic progenitor cells in nonpurified human mobilized peripheral blood mononuclear cells. J Gene Med. 2009;11:185-196.
48. Castanotto D, Li H, Rossi J. Functional siRNA expression from transfected PCR products. RNA. 2002;8:1454-1460.
49. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657-700.
50. Bauer G, Dao MA, Case SS, et al. In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors. Mol Ther. 2008;16:1308-1315.
51. Lim JK, Glass WG, McDermott DH, et al. CCR5: no longer a good for nothing gene-chemokine control of West Nile virus infection. Trends Immunol. 2006;27:308-312.